Sialon Pharmaceutical: The subsidiary obtained the approval notice of the marketing application of apixaban chemical API
Sialon Pharmaceuticals announced that its subsidiary obtained the approval notice for the marketing application of apixaban chemical API. Apixaban is a direct factor Xa inhibitor used primarily to prevent venous thromboembolic events (VTE) in adult patients undergoing elective hip or knee replacement.
LBT: Hong Kong and Shi proposed **no more than 1%].
Hong Kong Heshi intends to within 90 days after 15 trading days from the date of the announcement of this ** plan, through centralized auction transactions** The company's shares will not exceed 4,490,700 shares, accounting for 1 of the company's total share capital00%。
ST Tongda: **The change verification work was completed and trading resumed on December 14
ST Tongda announced that recently, the company has verified the relevant matters related to abnormal fluctuations in ** transactions. In view of the completion of the relevant verification work, after application, the company will resume trading from the opening of the market on December 14.
Rainbow shares: complete set of cooperative energy storage and storage projects with AVIC].
Rainbow shares announced that the company will cooperate with AVIC to carry out energy storage and storage projects in Xinsha Rainbow Shopping Center, No. 2105, West Ring Road, Shajing Street, Bao'an District, Shenzhen, and invest in the construction of energy storage storage power stations by AVIC, and the two sides will distribute the energy costs saved in proportion, with a cooperation period of 13 years and an estimated cumulative transaction amount of about 32 million yuan.
Xinhua Pharmaceutical: Levoamlodipine besylate tablets (2.)5mg) to obtain a drug registration certificate].
Xinhua Pharmaceutical announced that levamlodipine besylate tablets (25mg) to obtain a drug registration certificate].